■间变性淋巴瘤激酶(ALK)基因的重排包括非小细胞肺癌(NSCLC)的一小部分。携带ALK融合蛋白的NSCLC患者对ALK酪氨酸激酶抑制剂(TKIs)敏感。随着下一代测序(NGS)的应用,人们发现了ALK的各种融合伴侣。
■这里,我们报告1例女性转移性肺腺癌患者,NGS显示LMO7-ALK(L15,A20)重排.患者接受克唑替尼作为一线治疗,并已获得部分缓解,无进展生存期超过1年。
■我们首先发现对克唑替尼的满意反应证实了LMO7-ALK融合的致癌活性。NGS的巨大进步和广泛应用促进了罕见融合类型的发现。
UNASSIGNED: Rearrangements of the anaplastic lymphoma kinase (ALK) gene comprise a small subset of non-small cell lung cancer (NSCLC). Patients with NSCLC harboring ALK fusion proteins are sensitive to ALK tyrosine kinase inhibitors (TKIs). Various fusion partners of ALK are being discovered with the application of next-generation sequencing (NGS).
UNASSIGNED: Here, we report a female patient with metastatic lung adenocarcinoma harboring LMO7-ALK (L15, A20) rearrangement revealed by NGS. The patient received crizotinib as first-line treatment and has achieved partial response with a progression-free survival over 1 year.
UNASSIGNED: We firstly found that the satisfactory response to crizotinib verified the oncogenic activity of LMO7-ALK fusion. Great progression and wide application of NGS facilitate the findings of rare fusion types.